Evaluating Calaspargase Pegol Activity in Childhood Leukemia/Lymphoma
This study is looking at how long the medicine calaspargase pegol (Cal-PEG) stays active in the body of children and young adults with acute lymphoblastic leukemia or lymphoma. Researchers want to understand the typical duration of therapeutic serum asparaginase activity (SAA) levels after patients receive Cal-PEG. They also want to see if there's a link between how high the SAA levels get and how long they last, and if this relates to any side effects. You can join if you are 21 years old or younger, have acute lymphoblastic leukemia/lymphoma, and are receiving Cal-PEG as part of your treatment. The study aims to enroll 20 participants.
- Study design
- This is an observational study, meaning researchers will watch and collect information without giving you a specific intervention. It plans to include 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main measurement for this study will be taken for up to 15 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Madeleine B. O'Keefe, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Duration of therapeutic SAAUp to 15 months
Descriptive statistics including medians and interquartile ranges will be utilized to summarize continuous variables.